Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma-Reference-Cited by-同舟云学术

Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma

Published:2015-04-10 Issue:14 Volume:21 Page:3216-3229
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Gupte Ankita,Baker Emma K.,Wan Soo-San,Stewart Elizabeth,Loh Amos,Shelat Anang A.,Gould Cathryn M.,Chalk Alistair M.,Taylor Scott,Lackovic Kurt,Karlström Åsa,Mutsaers Anthony J.,Desai Jayesh,Madhamshettiwar Piyush B.,Zannettino Andrew C.W.,Burns Chris,Huang David C.S.,Dyer Michael A.,Simpson Kaylene J.,Walkley Carl R.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Cyclin L1 participates in Adriamycin resistance and progression of osteosarcoma via PI3K/AKT-mTOR pathway;Aging;2024-06-26

3. Identification of hub genes related to metastasis and prognosis of osteosarcoma and establishment of a prognostic model with bioinformatic methods;Medicine;2024-06-07

4. Synergistic anti-osteosarcoma cell effects of the methotrex-ate/PI3K/mTOR inhibitor nanoparticle codelivery system;Materials Technology;2024-06-05

5. Palladium (II) compounds containing oximes as promising antitumor agents for the treatment of osteosarcoma: An in vitro and in vivo comparative study with cisplatin;European Journal of Medicinal Chemistry;2024-01